An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia
Objective: to evaluate efficacy and safety of the use of a bioactive concentrate of small marine fish (Alflutop) in patients with vertebrogenic sciatica (SC).Patients and methods. The study included 30 patients with persistent (more than 3 months) vetebrogenic SC who underwent inpatient treatment in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574068397867008 |
|---|---|
| author | F. A. Khabirov A. A. Rogozhin A. A. Ismagilova L. F. Sabirova |
| author_facet | F. A. Khabirov A. A. Rogozhin A. A. Ismagilova L. F. Sabirova |
| author_sort | F. A. Khabirov |
| collection | DOAJ |
| description | Objective: to evaluate efficacy and safety of the use of a bioactive concentrate of small marine fish (Alflutop) in patients with vertebrogenic sciatica (SC).Patients and methods. The study included 30 patients with persistent (more than 3 months) vetebrogenic SC who underwent inpatient treatment in the neurological department of the Republican Clinical Neurological Center (Kazan). The patients were randomized into two groups: 15 patients of the 1st group received Alflutop (2 ml intramuscularly every other day, 10 injections in total) in addition to standard therapy, and 15 patients of the 2nd group (control) received standard therapy. The effectiveness of therapy was assessed using a visual analogue scale, Roland-Morris and EQ-5D questionnaires, an index of severity and frequency of sciatica.Results and discussion. Patients who received the study drug in addition to standard therapy showed a more rapid decrease in pain intensity, a trend towards a decrease in the severity index of sciatica, while no adverse events were recorded during the entire follow-up.Conclusion. The inclusion of Alflutop in the traditional scheme of inpatient treatment of patients with vertebrogenic SC allows to achieve a significantly greater reduction in the intensity of the pain syndrome after 20 days and 2 months after the start of therapy. |
| format | Article |
| id | doaj-art-e5f0a688ed0e4b51b819cff2c614654d |
| institution | Matheson Library |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2022-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-e5f0a688ed0e4b51b819cff2c614654d2025-08-04T14:00:38ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2022-06-01163606610.14412/1996-7012-2022-3-60-662481An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgiaF. A. Khabirov0A. A. Rogozhin1A. A. Ismagilova2L. F. Sabirova3Kazan State Medical Academy, branch of Russian Medical Academy of Continuing Professional EducationKazan State Medical Academy, branch of Russian Medical Academy of Continuing Professional EducationRepublican Clinical Neurological CenterRepublican Clinical Neurological CenterObjective: to evaluate efficacy and safety of the use of a bioactive concentrate of small marine fish (Alflutop) in patients with vertebrogenic sciatica (SC).Patients and methods. The study included 30 patients with persistent (more than 3 months) vetebrogenic SC who underwent inpatient treatment in the neurological department of the Republican Clinical Neurological Center (Kazan). The patients were randomized into two groups: 15 patients of the 1st group received Alflutop (2 ml intramuscularly every other day, 10 injections in total) in addition to standard therapy, and 15 patients of the 2nd group (control) received standard therapy. The effectiveness of therapy was assessed using a visual analogue scale, Roland-Morris and EQ-5D questionnaires, an index of severity and frequency of sciatica.Results and discussion. Patients who received the study drug in addition to standard therapy showed a more rapid decrease in pain intensity, a trend towards a decrease in the severity index of sciatica, while no adverse events were recorded during the entire follow-up.Conclusion. The inclusion of Alflutop in the traditional scheme of inpatient treatment of patients with vertebrogenic SC allows to achieve a significantly greater reduction in the intensity of the pain syndrome after 20 days and 2 months after the start of therapy.https://mrj.ima-press.net/mrj/article/view/1298vertebrogenic sciaticatherapybioactive concentrate of small marine fishalflutopefficiency |
| spellingShingle | F. A. Khabirov A. A. Rogozhin A. A. Ismagilova L. F. Sabirova An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia Современная ревматология vertebrogenic sciatica therapy bioactive concentrate of small marine fish alflutop efficiency |
| title | An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| title_full | An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| title_fullStr | An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| title_full_unstemmed | An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| title_short | An open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| title_sort | open prospective study of the efficacy and safety of therapy with a bioactive concentrate of small marine fish in patients with vertebrogenic lumboischialgia |
| topic | vertebrogenic sciatica therapy bioactive concentrate of small marine fish alflutop efficiency |
| url | https://mrj.ima-press.net/mrj/article/view/1298 |
| work_keys_str_mv | AT fakhabirov anopenprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT aarogozhin anopenprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT aaismagilova anopenprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT lfsabirova anopenprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT fakhabirov openprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT aarogozhin openprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT aaismagilova openprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia AT lfsabirova openprospectivestudyoftheefficacyandsafetyoftherapywithabioactiveconcentrateofsmallmarinefishinpatientswithvertebrogeniclumboischialgia |